摘要高危多发性骨髓瘤（High risk multiple myeloma，HRMM）是指在当前规范诊疗下，总生存期不足2～3年的骨髓瘤患者。结合多种静态和动态预后因素进行危险度分层，早期识别HRMM患者，并采用个体化风险分层治疗策略，有望显著改善HRMM患者不良生存结局。尽管近年来，国内对HRMM的临床价值已达成共识，但在HRMM的定义、高危因素、危险度分层和治疗等方面仍存在混乱和不明确之处，亟需规范。为提高中国医师对HRMM的诊治水平，中国抗癌协会血液肿瘤专业委员会和中国临床肿瘤学会多发性骨髓瘤专家委员会组织相关专家制定了本共识。该共识旨在明确HRMM的定义、高危因素和危险度分层体系，提供HRMM的治疗推荐，从而提高中国HRMM患者的生存质量和预后。

abstractsHigh-risk multiple myeloma (HRMM) refers to patients with multiple myeloma whose overall survival time is less than 2-3 years under current standardized diagnosis and treatment. By combining various static and dynamic prognostic factors, risk stratification is performed to identify HRMM patients early and treat patients with personalized strategies, with the aim of significantly improving adverse survival outcomes in HRMM patients. Although the clinical value of HRMM has reached a consensus domestically in recent years, there still exist confusions and ambiguities in the definition, high-risk factors, risk stratification, and treatment of HRMM, necessitating standardization. In order to enhance the diagnostic and treatment capabilities of Chinese physicians in HRMM, the Professional Committee of Hematologic Malignancies of the Chinese Anti-Cancer Association (CACA) and the Multiple Myeloma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) have organized relevant experts to develop this consensus. This consensus aims to clarify the definition of HRMM, high-risk factors, and risk stratification system, and provide treatment recommendations for HRMM, thereby improving the quality of life and prognosis of Chinese HRMM patients.